BR9811589A - Derivados de hidroxicumaranona o-substituìda como agentes antitumores e antimetastáticos - Google Patents

Derivados de hidroxicumaranona o-substituìda como agentes antitumores e antimetastáticos

Info

Publication number
BR9811589A
BR9811589A BR9811589-8A BR9811589A BR9811589A BR 9811589 A BR9811589 A BR 9811589A BR 9811589 A BR9811589 A BR 9811589A BR 9811589 A BR9811589 A BR 9811589A
Authority
BR
Brazil
Prior art keywords
tumor
derivatives
substituted
hydroxycumaranone
metastatic agents
Prior art date
Application number
BR9811589-8A
Other languages
English (en)
Inventor
Giampiero De Cillis
Robert Di Domenico
Bernhard Koenig
Ambrogio Oliva
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9811589A publication Critical patent/BR9811589A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE HIDROXICUMARANONA O-SUBSTITUìDA COMO AGENTES ANTITUMORES E ANTIMETASTáTICOS"<D>. Compostos da fórmula (I) em que R,R', A, B, T e x têm os significados dados na especificação possuem atividade antagonista uPA (ativador de plasminogêneo tipo uroquinase) e podem ser empregados como agentes antitumores e antimetastáticos.
BR9811589-8A 1997-07-31 1998-07-23 Derivados de hidroxicumaranona o-substituìda como agentes antitumores e antimetastáticos BR9811589A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97113190 1997-07-31
EP98106946 1998-04-16
PCT/EP1998/004619 WO1999006387A2 (en) 1997-07-31 1998-07-23 O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents

Publications (1)

Publication Number Publication Date
BR9811589A true BR9811589A (pt) 2000-09-19

Family

ID=26145681

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811589-8A BR9811589A (pt) 1997-07-31 1998-07-23 Derivados de hidroxicumaranona o-substituìda como agentes antitumores e antimetastáticos

Country Status (21)

Country Link
US (1) US6200989B1 (pt)
EP (1) EP1012147B1 (pt)
JP (1) JP3241711B2 (pt)
KR (1) KR100343067B1 (pt)
AR (1) AR013374A1 (pt)
AT (1) ATE308535T1 (pt)
AU (1) AU745839B2 (pt)
BR (1) BR9811589A (pt)
CA (1) CA2296476A1 (pt)
DE (1) DE69832184D1 (pt)
HR (1) HRP20000031A2 (pt)
HU (1) HUP0004221A2 (pt)
ID (1) ID24525A (pt)
IL (1) IL134193A0 (pt)
MA (1) MA26528A1 (pt)
NO (1) NO20000366L (pt)
PE (1) PE106099A1 (pt)
PL (1) PL338614A1 (pt)
TR (1) TR200000272T2 (pt)
UY (1) UY25114A1 (pt)
WO (1) WO1999006387A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736869B2 (en) * 1999-01-30 2001-08-02 Roche Diagnostics Gmbh O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents
US7514406B2 (en) * 2001-11-27 2009-04-07 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
WO2003051347A1 (en) * 2001-12-19 2003-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
WO2004076444A2 (en) * 2003-02-25 2004-09-10 F. Hoffmann-La Roche Ag Novel hydroxycoumaranone derivatives as antitumor and antimetastatic
MX2009004558A (es) * 2006-10-27 2009-06-10 Univ Tokyo Compuesto amida o su sal, e inhibidor de formacion de biopelicula, quitador de biopelicula y bactericida usando cada uno el compuesto amida o su sal.
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
SG11202003463XA (en) 2017-10-18 2020-05-28 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as PRMT5 inhibitors
CN111757739A (zh) 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 整合应激反应路径抑制剂
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2019236710A1 (en) * 2018-06-05 2019-12-12 Praxis Biotech LLC Inhibitors of integrated stress response pathway
CA3142748A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2901336A1 (de) * 1979-01-15 1980-07-24 Boehringer Mannheim Gmbh Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3209271A1 (de) * 1982-03-13 1983-09-15 Boehringer Mannheim Gmbh, 6800 Mannheim Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
EP0192671B1 (en) * 1984-08-13 1993-12-29 Biotechnology Australia Pty. Ltd. Minactivin
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands

Also Published As

Publication number Publication date
WO1999006387A2 (en) 1999-02-11
NO20000366D0 (no) 2000-01-25
KR20010022362A (ko) 2001-03-15
WO1999006387A3 (en) 1999-04-22
PE106099A1 (es) 1999-11-11
MA26528A1 (fr) 2004-12-20
JP2001512113A (ja) 2001-08-21
AR013374A1 (es) 2000-12-27
AU745839B2 (en) 2002-04-11
EP1012147A2 (en) 2000-06-28
AU9155998A (en) 1999-02-22
ATE308535T1 (de) 2005-11-15
JP3241711B2 (ja) 2001-12-25
DE69832184D1 (de) 2005-12-08
ID24525A (id) 2000-07-20
HRP20000031A2 (en) 2000-10-31
UY25114A1 (es) 2001-01-31
CA2296476A1 (en) 1999-02-11
US6200989B1 (en) 2001-03-13
TR200000272T2 (tr) 2000-09-21
NO20000366L (no) 2000-01-25
PL338614A1 (en) 2000-11-06
IL134193A0 (en) 2001-04-30
HUP0004221A2 (hu) 2001-04-28
KR100343067B1 (ko) 2002-07-03
EP1012147B1 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
BR9811589A (pt) Derivados de hidroxicumaranona o-substituìda como agentes antitumores e antimetastáticos
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
DE60033684D1 (de) Phenylalaninderivate
TR200100047T2 (tr) Tiyobenzimidazol türevleri
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
DE69413167T2 (de) Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen
BR9806752A (pt) Ftalazinonas.
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
AU7874001A (en) Novel phenylalanine derivatives
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
EP1477482A4 (en) NEW PHENYLALANINE DERIVATIVE
ATE215938T1 (de) Serin-protease-inhibitoren: derivate des isothiazolidin-3-on-1,1-dioxids und des 3-oxo-1,2,5-thiadiazolidin-1,1-dioxids
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
CY1106444T1 (el) 17b-νιτρο-11β-αρυλοστepοειδη και παραγωγα αυτων ως ορμονικοι αγωνιστες ή ανταγωνιστες
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
BR9812922A (pt) Isoquinolinas como inibidores de uroquinase
MX9300779A (es) 3-(1h-tetrazol-5-y1)-4h-pyrido[1,2-a]pirimidina-4-onas composiciones farmaceuticas que las contienen y su preparacion de las mismas
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
BR9813719A (pt) Agentes terapêuticos
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
ES2174113T3 (es) Nuevos derivados de ((3-alcoxi-fenoxi)-etil)-dialquilamina y su utilizacion como anestesicos locales.
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
DE68914522D1 (de) Isobenzothiazolon als chromogenische Thiol-Indikatoren und dessen Derivate.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements